Paul Anderson Acquires 80,426 Shares of Orthocell Limited (ASX:OCC) Stock

Orthocell Limited (ASX:OCC) insider Paul Anderson bought 80,426 shares of the business’s stock in a transaction on Tuesday, October 15th. The shares were acquired at an average cost of A$0.73 ($0.49) per share, with a total value of A$58,710.98 ($39,403.34).

Orthocell Price Performance

The company has a quick ratio of 5.07, a current ratio of 4.34 and a debt-to-equity ratio of 15.22.

Orthocell Company Profile

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries.